He describes the multiple variables that factor in to designing new medicines with AI, how Iambic's platform has allowed it to shorten the time to get a medicine into the clinic versus traditional discovery work, and how he thinks AI will augment the work of human scientists.

Tom Miller describes the rationale for the raise and what it will allow Iambic to do, how he believes the company's AI approach is unique